health
This Life Sciences Stock Has a Secret Weapon, and AI Will Only Make It More Valuable
IQVIA controls one of the world's largest databases of healthcare information that's closely integrated the clinical research process.
TL;DR
- IQVIA provides data, tools, and services essential for drug development and clinical trials.
- The company has a database of over 1.2 billion healthcare records, creating a competitive moat.
- IQVIA recently launched an AI platform, IQVIA.ai, in partnership with Nvidia, to accelerate drug development.
- Despite strong fundamentals, record backlog, and improved guidance, the stock is trading near a five-year low valuation.
- AI is increasing demand for IQVIA's services by helping clients identify more drug candidates and expand development pipelines.
- The company was formed in 2016 by the merger of IMS Health and Quintiles.
- IQVIA commands a significant market share in the contract research organization (CRO) space.
- A valuation disconnect exists, with a discounted cash flow model suggesting a fair value significantly higher than the current stock price.
- Improving growth, backlog, cash generation, and balance sheet deleveraging are expected to drive multiple expansion.
- IQVIA is actively repurchasing shares, signaling management's confidence in the company's value.